Nitric Oxide Bioavailability and Vascular Dysfunction in Sickle Cell Patients: A Pathophysiological Nexus

Sickle cell disease (SCD) is a genetic disorder characterized by chronic hemolytic anemia, recurrent vaso-occlusive crises, and progressive organ damage. One of the central mechanisms driving vascular complications in SCD is the impaired bioavailability of nitric oxide (NO), a key molecule responsible for regulating vascular tone, inhibiting platelet aggregation, and maintaining endothelial integrity. The persistent intravascular hemolysis that occurs in SCD releases free hemoglobin and arginase into the circulation, which significantly reduces NO levels and limits its physiological effects. Reduced NO availability leads to endothelial dysfunction, characterized by vasoconstriction, increased leukocyte adhesion, and a pro-thrombotic state. These vascular changes not only contribute to acute events such as pain crises and acute chest syndrome but also underlie long-term complications including pulmonary hypertension, stroke, and chronic organ damage. Oxidative stress and inflammation further disrupt NO synthesis by impairing endothelial nitric oxide synthase (eNOS) activity and uncoupling its function, creating a vicious cycle of vascular injury.